Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
Hartmaier RJ, Markovets AA, Ahn MJ, Sequist LV, Han JY, Cho BC, Yu HA, Kim SW, Yang JC, Lee JS, Su WC, Kowalski DM, Orlov S, Ren S, Frewer P, Ou X, Cross DAE, Kurian N, Cantarini M, Jänne PA.
Hartmaier RJ, et al. Among authors: ou x.
Cancer Discov. 2023 Jan 9;13(1):98-113. doi: 10.1158/2159-8290.CD-22-0586.
Cancer Discov. 2023.
PMID: 36264123
Free PMC article.